Cellares logo

Cellares

Builds infrastructure intended to expand access to cell therapies and support delivery of advanced treatments to more patients.

Deep Tech
Cell Therapy
Total Raised
$277M
Last Valuation
$1.8B
Headquarters
South San Francisco, United States

Overview

Cellares is focused on expanding patient access to cell therapies. The company operates in the cell therapy supply chain, serving a healthcare market where manufacturing capacity, reliability and cost can constrain adoption. Its current funding context is a $277 million undisclosed round announced on June 10, 2026, with Cathie Wood’s ARK Invest joining the financing. The capital is intended to help bring cell therapies to more patients, positioning Cellares as a scaled deep-tech life sciences platform rather than a pure AI software business.

Funding History

1 round · Jun 2026
$277M
Total Raised
1
Valuation: $1.8B
Cumulative: $277M

Cathie Wood’s ARK Invest joins Cellares’ $277M round to help bring cell therapies to more patients

Investors not disclosed
Source

Frequently Asked Questions

How much has Cellares raised in total?
Cellares has raised a total of $277M across 1 funding round.
Who are Cellares's investors?
Cellares's investors include Undisclosed.
What does Cellares do?
Cellares is focused on expanding patient access to cell therapies. The company operates in the cell therapy supply chain, serving a healthcare market where manufacturing capacity, reliability and cost can constrain adoption. Its current funding context is a $277 million undisclosed round announced on June 10, 2026, with Cathie Wood’s ARK Invest joining the financing. The capital is intended to help bring cell therapies to more patients, positioning Cellares as a scaled deep-tech life sciences platform rather than a pure AI software business.
Where is Cellares headquartered?
Cellares is headquartered in South San Francisco, United States.